FPG reductions at 2 weeks, maintained for 52 weeks1
Once-daily Victoza® provides improved A1C control with daily management of FPG and PPG in adults with type 2 diabetes.1
aPPG was measured as a secondary endpoint in clinical studies. PPG data were obtained via self-monitoring of blood glucose.
In a 52-week study as monotherapy, once-daily Victoza® offered significant reductions in A1C1
Victoza® provides daily management of FPG and PPG.
ADA FPG goal was 90-130 mg/dL at the time of trial design.1
eP=0.0038 compared with glimepiride.
fP=0.1616 compared with glimepiride.
Victoza® lowered premeal, postprandial, and fasting glucose throughout the day.
Glimepiride was studied, but is not shown in this graph.
PPG was measured as a secondary endpoint in clinical studies.
PPG data were obtained via self-monitoring of blood glucose.1
Safety and tolerability were studied
No major hypoglycemia events occurred.1
Individual results may vary.
A 52-week, double-blind, double-dummy, active-controlled, parallel-group, multicenter study. Patients with type 2 diabetes (N=746) were randomized to receive once-daily Victoza® 1.2 mg (n=251), Victoza® 1.8 mg (n=246), or glimepiride 8 mg (n=248). The primary outcome was change in A1C after 52 weeks.1
ADA=American Diabetes Association; FPG=fasting plasma glucose; PPG=postprandial plasma glucose; GLP-1=glucagon-like peptide-1; RA=receptor agonist.
Reference: 1. Garber A, Henry R, Ratner R, et al; for the LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473-481.